In Vivo Assays

Oncology Animal Models

Caliper Discovery Alliances & Services (CDAS) has established a wide range of animal models in oncology for preclinical cancer research studies including syngeneic/xenogeneic, orthotopic/heterotopic, and primary/metastatic models. These models are used to assess anticancer therapies over the course of treatment in vivo. All our studies are highly customizable with study protocols optimized to meet our clients’ study requirements (route of administration, treatment protocol, imaging schedule, etc.)

To conduct in vivo anticancer drug efficacy studies, CDAS uses relevant bioluminescent (light-emitting) cancer cell lines implanted into immunocompromised or immunocompetent animals. Tumor growth/metastasis and drug efficacy is monitored throughout the duration of the study using Caliper's proprietary real-time in vivo imaging IVIS platform. The non-invasive optical bioluminescence/fluorescence IVIS technology increases the throughput of in vivo efficacy studies since it requires fewer test animals and shorter timelines compared to conventional animal testing paradigms. The combination of bioluminescent cancer cell lines and the IVIS platform enables us to perform longitudinal evaluation of tumor development and to monitor the efficacy of drug compounds on tumor growth while offering more and higher quality data. As such, more accurate and clinically relevant predictions can be made earlier in preclinical drug development process.

The recombinant luciferase cell lines used at CDAS to establish oncology animal models may have various origins: i) Caliper’s Bioware portfolio of cell lines, ii) Custom recombinant cell lines developed by CDAS or iii) Cell lines directly provided by clients. At CDAS we offer:

• Wide choice of Caliper’s Bioware bioluminescent cell lines
• Custom creation of recombinant bioluminescent cell lines

The following table is a listing including our oncology animal models. At CDAS we are also capable of developing any custom oncology model using our over 60 bioluminescent and fluorescent recombinant cell lines, client provided cell lines, or cell lines created by CDAS from a parental cell line of interest.

Model	Model/Application	Animal Host Options	Tumor Graft	Cell Line	Drug Injection
Xenogeneic	Anticancer Activity	NIH-IIInu/bg (nude/beige)	Subcutaneous		i.v., i.p.
				HT-29
				NCI-H460
				MDA-MB-231
				MCF-7 (ER+)
				MB-231 (ER-)
				LNCaP
Xenogeneic		NIH-IIInu/bg (nude/beige)	Orthotopic/Primary		i.v., i.p.
	Colon Cancer		Colon	HT-29
	Lung Cancer		Lung	NCI-H460
	Breast Cancer		Breast	MDA-MB-231
	Breast Cancer		Breast	MCF-7 (ER+)
	Breast Cancer		Breast	MB-231 (ER-)
Xenogeneic		NIH-IIInu/bg (nude/beige)	Intravenous Metastasis		i.v.
			organs/tissues with metastasis	HT-29
			organs/tissues with metastasis	NCI-H460
Syngeneic			Orthotopic/Primary		i.v., i.p.
	Immunotox	C57BL6	Skin	B16F10
	Immunotox	BALBc	Breast	4T1